↓ Skip to main content

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

Overview of attention for article published in BMC Gastroenterology, March 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
32 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Published in
BMC Gastroenterology, March 2015
DOI 10.1186/s12876-015-0266-6
Pubmed ID
Authors

Beatrix Bencsikova, Zbynek Bortlicek, Jana Halamkova, Lenka Ostrizkova, Igor Kiss, Bohuslav Melichar, Tomas Pavlik, Ladislav Dusek, Dalibor Valik, Rostislav Vyzula, Lenka Zdrazilova-Dubska

Abstract

The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 19%
Student > Master 6 19%
Student > Ph. D. Student 5 16%
Other 4 13%
Researcher 3 9%
Other 1 3%
Unknown 7 22%
Readers by discipline Count As %
Medicine and Dentistry 15 47%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Agricultural and Biological Sciences 1 3%
Nursing and Health Professions 1 3%
Immunology and Microbiology 1 3%
Other 2 6%
Unknown 9 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2019.
All research outputs
#4,887,904
of 15,561,218 outputs
Outputs from BMC Gastroenterology
#265
of 1,007 outputs
Outputs of similar age
#98,838
of 270,986 outputs
Outputs of similar age from BMC Gastroenterology
#1
of 1 outputs
Altmetric has tracked 15,561,218 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,007 research outputs from this source. They receive a mean Attention Score of 4.8. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,986 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them